CLINICAL TRIALS PROFILE FOR PAROEX

All Clinical Trials for PAROEX

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01030666 ↗	Effect of Postsurgical Systemic Doxycycline After Regenerative Periodontal Therapy	Terminated	Dr. August Wolff GmbH & Co. KG Arzneimittel	Phase 4	2007-04-01	Study Hypothesis: The administration of 200 mg doxycycline once a day for 7 days after regenerative periodontal therapy of infrabony defects improves the results of therapy (clinical vertical attachment gains [CAL-V], bony fill) and reduces postoperative flap dehiscence and defect exposure. In each of 90 patients one infrabony defect shall be treated by regenerative techniques (guided tissue regeneration [GTR], enamel matrix derivative [EMD]). Prior to , 6, 12, and 24 months after surgery clinical measurements (Plaque Index [PlI], probing depth [PD], vertical clinical attachment level [CAL-V], Gingival Index [GI]) and standardized radiographs are obtained.
NCT01030666 ↗	Effect of Postsurgical Systemic Doxycycline After Regenerative Periodontal Therapy	Terminated	Gaba International AG	Phase 4	2007-04-01	Study Hypothesis: The administration of 200 mg doxycycline once a day for 7 days after regenerative periodontal therapy of infrabony defects improves the results of therapy (clinical vertical attachment gains [CAL-V], bony fill) and reduces postoperative flap dehiscence and defect exposure. In each of 90 patients one infrabony defect shall be treated by regenerative techniques (guided tissue regeneration [GTR], enamel matrix derivative [EMD]). Prior to , 6, 12, and 24 months after surgery clinical measurements (Plaque Index [PlI], probing depth [PD], vertical clinical attachment level [CAL-V], Gingival Index [GI]) and standardized radiographs are obtained.
NCT01030666 ↗	Effect of Postsurgical Systemic Doxycycline After Regenerative Periodontal Therapy	Terminated	Heidelberg University	Phase 4	2007-04-01	Study Hypothesis: The administration of 200 mg doxycycline once a day for 7 days after regenerative periodontal therapy of infrabony defects improves the results of therapy (clinical vertical attachment gains [CAL-V], bony fill) and reduces postoperative flap dehiscence and defect exposure. In each of 90 patients one infrabony defect shall be treated by regenerative techniques (guided tissue regeneration [GTR], enamel matrix derivative [EMD]). Prior to , 6, 12, and 24 months after surgery clinical measurements (Plaque Index [PlI], probing depth [PD], vertical clinical attachment level [CAL-V], Gingival Index [GI]) and standardized radiographs are obtained.
NCT01030666 ↗	Effect of Postsurgical Systemic Doxycycline After Regenerative Periodontal Therapy	Terminated	Peter Eickholz	Phase 4	2007-04-01	Study Hypothesis: The administration of 200 mg doxycycline once a day for 7 days after regenerative periodontal therapy of infrabony defects improves the results of therapy (clinical vertical attachment gains [CAL-V], bony fill) and reduces postoperative flap dehiscence and defect exposure. In each of 90 patients one infrabony defect shall be treated by regenerative techniques (guided tissue regeneration [GTR], enamel matrix derivative [EMD]). Prior to , 6, 12, and 24 months after surgery clinical measurements (Plaque Index [PlI], probing depth [PD], vertical clinical attachment level [CAL-V], Gingival Index [GI]) and standardized radiographs are obtained.
NCT04830969 ↗	Impact of Periodontal Therapy on Patients With Diabetes	Completed	Sunstar, Inc.	Phase 2	2016-11-08	With poorly controlled diabetes, periodontal status often worsens, and with severe periodontal conditions there is often poorer glycemic control. There are few published reports investigating the efficacy of periodontal therapy in diabetics and fewer that include evaluation of the oral microbial profiles (the microbiome). The investigators will examine systemic changes in diabetes status and microbiome influences on clinical response to periodontal therapy in a randomized clinical trial of participants with and without diabetes and with periodontal disease. Two different treatments will be used: 1. Scaling and root planning (SRP) alone, or 2. SRP and supportive periodontal therapy (SPT), the use of chlorhexidine gluconate rinse (Paroex®) and a rubber interdental bristle cleaner (Soft-Picks) The main goal of this clinical trial is to evaluate the effects of SRP alone versus SRP+SPT on clinical, microbiological and immunological status in participants. A clearer understanding of how periodontal therapy affects diabetes status could lead to the development of new therapies for periodontal disease and diabetes.

Clinical Trial Conditions for PAROEX

Condition Name

Condition Name for PAROEX
Intervention	Trials
Periodontitis	2
Diabetes Mellitus, Type II	1

Condition MeSH

Condition MeSH for PAROEX
Intervention	Trials
Periodontitis	2
Diabetes Mellitus, Type 2	1
Diabetes Mellitus	1

Clinical Trial Locations for PAROEX

Trials by Country

Trials by Country for PAROEX
Location	Trials
United States	1
Germany	1

Trials by US State

Trials by US State for PAROEX
Location	Trials
New York	1

Clinical Trial Progress for PAROEX

Clinical Trial Phase

Clinical Trial Phase for PAROEX
Clinical Trial Phase	Trials
Phase 4	1
Phase 2	1

Clinical Trial Status

Clinical Trial Status for PAROEX
Clinical Trial Phase	Trials
Terminated	1
Completed	1

Clinical Trial Sponsors for PAROEX

Sponsor Name

Sponsor Name for PAROEX
Sponsor	Trials
Peter Eickholz	1
Sunstar, Inc.	1
State University of New York at Buffalo	1

Sponsor Type

Sponsor Type for PAROEX
Sponsor	Trials
Other	3
Industry	3